Richardson D R, Ponka P, Vyoral D
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Blood. 1996 Apr 15;87(8):3477-88.
Succinylacetone (SA) is an inhibitor of heme synthesis that acts on the enzyme delta-aminolevulinic acid dehydratase. When reticulocytes are incubated with 59Fe-transferrin (59Fe-Tf) in the presence of SA, there is an accumulation of 59Fe in the mitochondrion and in a cytosolic non-heme intermediate that has been described as a putative Fe transporter (Adams et al, Biochim Biophys Acta 1012:243, 1989). Considering these observations, the present study was designed to examine the intermediates of Fe metabolism in control and SA-treated reticulocytes. This investigation showed that in the cytosol of control cells, most 59Fe was incorporated into hemoglobin (Hb) with a minor amount entering ferritin. In addition, a previously unrecognized cytosolic intermediate was identified (band X) that was absent when heme synthesis was inhibited with SA. Upon reincubation of SA-treated reticulocytes with protoporphyrin IX, band X initially increased in intensity and then decreased later in the incubation. In contrast, when 59Fe-labeled control cells were reincubated in the presence of SA and unlabeled diferric Tf, there was a marked decrease in the intensity of band X. These experiments suggest that component X may be an intermediate involved in the transfer of heme in the cytosol. Alternatively, these data could also be interpreted as indicating that band X may be a short-lived hemoprotein. We have confirmed the presence of an 59Fe-containing molecule in the cytosol of SA-treated reticulocytes (band Y) that is not present in control cells. However, when cells were incubated with 59Fe-Tf plus SA and then chased in the presence of SA and unlabeled diferric Tf, there was no decrease in this cytosolic pool of Fe, suggesting that it was not a intermediate supplying Fe for either ferritin or heme synthesis. Finally, there is little low molecular weight (Mr) Fe in reticulocytes, and our studies suggest that the low-Mr Fe present does not behave as an intermediate. Moreover, after inhibition of heme synthesis with SA, 59Fe in the low-Mr compartment was markedly decreased, suggesting that this component may be heme or a low-Mr heme-containing molecule. Considering the apparent lack of a cytosolic Fe transporter in rabbit reticulocytes, an alternative model of intracellular Fe transport is proposed that does not implicate a potentially toxic intermediate pool of low-Mr Fe complexes.
琥珀酰丙酮(SA)是血红素合成的抑制剂,作用于δ-氨基-γ-酮戊酸脱水酶。当网织红细胞在SA存在的情况下与59Fe-转铁蛋白(59Fe-Tf)一起孵育时,59Fe会在线粒体和一种胞质非血红素中间体中积累,该中间体被描述为一种假定的铁转运体(亚当斯等人,《生物化学与生物物理学报》1012:243,1989年)。考虑到这些观察结果,本研究旨在检查对照和SA处理的网织红细胞中铁代谢的中间体。这项研究表明,在对照细胞的胞质溶胶中,大多数59Fe被整合到血红蛋白(Hb)中,少量进入铁蛋白。此外,还鉴定出一种以前未被识别的胞质中间体(条带X),当用SA抑制血红素合成时该中间体不存在。在用原卟啉IX对SA处理的网织红细胞进行再孵育后,条带X的强度最初增加,随后在孵育后期降低。相反,当59Fe标记的对照细胞在SA和未标记的双铁转铁蛋白存在的情况下进行再孵育时,条带X的强度显著降低。这些实验表明,成分X可能是参与胞质溶胶中血红素转运的中间体。或者,这些数据也可以解释为表明条带X可能是一种寿命短暂的血红蛋白。我们已经证实,在SA处理的网织红细胞的胞质溶胶中存在一种对照细胞中不存在的含59Fe的分子(条带Y)。然而,当细胞与59Fe-Tf加SA一起孵育,然后在SA和未标记的双铁转铁蛋白存在的情况下进行追踪时,这种胞质铁池没有减少,这表明它不是为铁蛋白或血红素合成提供铁的中间体。最后,网织红细胞中低分子量(Mr)的铁很少,我们的研究表明,存在的低Mr铁并不表现为中间体。此外,在用SA抑制血红素合成后,低Mr区室中的59Fe显著减少,这表明该成分可能是血红素或一种低Mr含血红素的分子。考虑到兔网织红细胞中明显缺乏胞质铁转运体,提出了一种细胞内铁转运的替代模型,该模型不涉及潜在有毒的低Mr铁复合物中间体池。